Lindbrook Capital, LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 240 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.1%.

Quarter-by-quarter ownership
Lindbrook Capital, LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$3,030
-70.1%
85
-61.4%
0.00%
-100.0%
Q2 2023$10,149
+31.8%
220
+14.6%
0.00%0.0%
Q1 2023$7,699
-62.2%
192
-56.4%
0.00%
-66.7%
Q4 2022$20,385
+307.7%
440
+286.0%
0.00%
+200.0%
Q3 2022$5,000
+150.0%
114
+307.1%
0.00%
Q1 2022$2,0000.0%28
+16.7%
0.00%
Q4 2021$2,000
+100.0%
24
+242.9%
0.00%
Q1 2021$1,0000.0%7
-58.8%
0.00%
Q4 2019$1,000
-75.0%
17
-80.5%
0.00%
-100.0%
Q3 2019$4,0000.0%87
+38.1%
0.00%0.0%
Q2 2019$4,0000.0%630.0%0.00%0.0%
Q1 2019$4,000
+100.0%
630.0%0.00%
+100.0%
Q4 2018$2,000630.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q2 2023
NameSharesValueWeighting ↓
First Light Asset Management, LLC 217,459$24,760,0001.64%
Motley Fool Asset Management LLC 152,326$17,344,0001.25%
Rock Springs Capital Management LP 450,000$51,237,0001.12%
AtonRa Partners 21,017$2,393,0001.07%
SECTORAL ASSET MANAGEMENT INC 112,200$12,775,0000.97%
EMERALD ADVISERS, LLC 228,368$26,002,0000.94%
EMERALD MUTUAL FUND ADVISERS TRUST 239,023$27,215,0000.90%
FEDERATED HERMES, INC. 3,912,408$445,467,0000.86%
HealthCor Management, L.P. 207,610$23,638,0000.84%
Atika Capital Management LLC 66,000$7,515,0000.65%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders